<DOC>
	<DOCNO>NCT00516503</DOCNO>
	<brief_summary>RATIONALE : Baclofen-amitriptyline-ketamine ( BAK ) gel may lessen peripheral neuropathy cause chemotherapy . It yet know whether BAK gel effective placebo treat peripheral neuropathy cause chemotherapy . PURPOSE : This randomized phase III trial study BAK gel see well work compare placebo treat peripheral neuropathy cause chemotherapy patient cancer .</brief_summary>
	<brief_title>Baclofen-Amitriptyline Hydrochloride-Ketamine Gel Treating Peripheral Neuropathy Caused Chemotherapy Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effectiveness baclofen-amitriptyline hydrochloride-ketamine ( BAK ) gel versus placebo , term improve sensory neuropathy , cancer patient chemotherapy-induced peripheral neuropathy . Secondary - Compare motor autonomic symptom function , mood state , pain , peripheral neuropathy patient . - Assess adverse event profile topical BAK gel . - Explore whether topical BAK gel absorb systemically . OUTLINE : Patients stratify accord neurotoxic chemotherapy ( active v non-active ) , current use opioids oral pain medication ( yes v ) , pain rating ( 4-7 v 8-10 ) , prior ineffective pharmacologic treatment peripheral neuropathy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients apply 1 spoonful baclofen-amitriptyline hydrochloride-ketamine gel topically area pain , numbness , and/or tingle foot and/or hand twice daily 4 week . - Arm II : Patients apply 1 spoonful placebo gel topically area pain , numbness , and/or tingle foot and/or hand twice daily 4 week . Some patient arm may choose continue active gel , placebo , begin active gel additional 8 week study . Patients complete health , pain , mood , quality life questionnaire baseline periodically study . Patients also record adverse symptom weekly Symptom Experience Diary .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Received currently receive neurotoxic chemotherapy include , limited , taxanes ( e.g. , paclitaxel docetaxel ) ; platinumbased compound ( e.g. , carboplatin , cisplatin , oxaliplatin ) ; vinca alkaloid ( e.g. , vincristine vinblastine ) ; neurotoxic chemotherapy agent ( e.g. , bortezomib , lenalidomide , thalidomide ) Must pain symptom peripheral neuropathy attributable chemotherapy ≥ 1 month Neuropathy limit either hand and/or foot gel apply Neuropathic pain score ≥ 4 10 numbness/tingling/pain numeric analogue scale No preexist history peripheral neuropathy due cause chemotherapy ( e.g. , diabetes , alcohol , toxin , heredity ) PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 4 month Creatinine ≤ 1.5 time upper limit normal Not pregnant nursing No ability bear child define 1 criterion : Menopausal ( 12 month menstrual period natural menopause ) Underwent hysterectomy and/or oophorectomy Permanent surgical sterilization ( tubal ligation ) Fertile patient must use effective contraception Able complete questionnaire independently assistance Able sign inform consent understand nature placebocontrolled trial No history allergic reaction baclofen , amitriptyline hydrochloride , and/or ketamine No diagnosis New York Heart Association class IIV congestive heart failure No diagnosis coronary artery disease include , limited , myocardial infarction , within past 5 year No medical condition , opinion treat physician ally health professional , would make clinical trial unreasonably hazardous patient No skin abnormality intend application site ( hand foot ) study gel ( i.e. , skin breakdown ) PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior anticonvulsant , tricyclic antidepressant , monoamine oxidase inhibitor , neuropathic pain medication ( e.g. , carbamazepine , phenytoin , valproic acid , gabapentin , lamotrigine , topical lidocaine patch gel , capsaicin cream , amifostine ) Patients treated agent peripheral neuropathy ≤ 1 week past 30 day eligible provide longer take agent More 5 year since prior percutaneous transluminal coronary angioplasty coronary artery bypass graft Prior heart valve replacement surgery allow provide patient fully recover surgery No concurrent use study agent specify trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>